| Gene Symbol | NPY1R |
|---|---|
| Full Name | Neuropeptide Y Receptor Y1 |
| Chromosomal Location | 4q31.3 |
| NCBI Gene ID | [4886](https://www.ncbi.nlm.nih.gov/gene/4886) |
| OMIM | [162061](https://www.omim.org/entry/162061) |
| Ensembl ID | [ENSG00000118322](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000118322) |
| UniProt | [P25106](https://www.uniprot.org/uniprot/P25106) |
| Protein Length | 384 amino acids |
| Protein Family | GPCR Class A (Rhodopsin family) |
| Expression | High in brain (cortex, hippocampus, amygdala, hypothalamus) |
NPY1R encodes the Neuropeptide Y Receptor Y1, a G protein-coupled receptor (GPCR) that binds neuropeptide Y (NPY), one of the most abundant and evolutionarily conserved neuropeptides in the mammalian brain. NPY1R is a Class A rhodopsin-family GPCR that plays critical roles in regulating feeding behavior, energy homeostasis, emotional responses, synaptic plasticity, and seizure threshold 1.
The NPY system, comprising NPY and its receptors (Y1, Y2, Y4, Y5), is involved in numerous physiological and pathological processes. NPY1R is the most widely studied of the NPY receptors due to its central role in appetite regulation and its implications in obesity, anxiety disorders, epilepsy, and neurodegenerative diseases including Alzheimer's disease and Parkinson's disease 2.
NPY1R exhibits high affinity for NPY and related peptides including peptide YY (PYY). The receptor recognizes the C-terminal region of NPY, particularly the amidated Tyr^36 residue, as critical for high-affinity binding 3. Synthetic analogs and peptidic antagonists have been developed to selectively target NPY1R:
The ligand binding pocket involves transmembrane domains 3, 5, 6, and 7, with key interaction sites including:
NPY1R couples primarily to G_i/o proteins, leading to:
The G_i/o coupling leads to neuronal hyperpolarization through increased K+ conductance, reducing neuronal excitability. This mechanism underlies NPY's anti-epileptic effects 4.
NPY1R is highly expressed in brain regions involved in energy homeostasis, emotional processing, and memory:
| Brain Region | Expression Level | Function |
|---|---|---|
| Cortex | High | Cognitive processing, plasticity |
| Hippocampus | High | Learning, memory |
| Amygdala | High | Emotional processing, fear conditioning |
| Hypothalamus | Very high | Energy homeostasis, feeding |
| Thalamus | Moderate | Sensory relay |
| Basal ganglia | Moderate | Motor control, reward |
In the hippocampus, NPY1R is expressed on CA1 pyramidal neurons and interneurons, where it modulates synaptic plasticity and neuronal excitability. This has important implications for memory formation and seizure susceptibility 5.
NPY1R signaling modulates several key neural circuits:
Feeding circuit: NPY1R in the arcuate nucleus and paraventricular hypothalamus integrates metabolic signals (leptin, insulin) to regulate food intake. Activation of NPY1R on pro-opiomelanocortin (POMC) neurons inhibits anorexigenic signaling.
Fear circuit: In the amygdala, NPY1R modulates anxiety-like behavior through effects on GABAergic interneurons. NPY has anxiolytic effects largely mediated by Y1 receptors.
Memory circuit: In the hippocampus, NPY1R regulates long-term potentiation (LTP) and memory consolidation. The receptor's location on both presynaptic terminals and postsynaptic neurons suggests complex modulation of synaptic transmission.
NPY1R is a prime therapeutic target for obesity due to its central role in stimulating food intake. NPY neurons in the arcuate nucleus project to the paraventricular nucleus where NPY1R activation drives hyperphagia 6.
Key findings:
However, NPY1R antagonists have shown limited efficacy in clinical trials due to compensatory mechanisms and blood-brain barrier penetration challenges.
The NPY system is critically involved in stress responses and emotional regulation. NPY1R in the amygdala mediates anxiolytic effects, while Y1 receptor deficiency leads to increased anxiety-like behavior 7.
Clinical observations:
NPY acts as an endogenous anti-epileptic agent through Y1 receptors. NPY1R activation reduces seizure frequency and severity in animal models 8.
Mechanisms:
NPY analogs are being developed as novel anti-epileptic drugs, particularly for treatment-resistant epilepsy.
NPY1R has emerged as a potential modulator of Alzheimer's disease pathology:
Amyloid regulation: NPY1R signaling affects amyloid precursor protein (APP) processing and amyloid-beta production. Y1 receptor activation reduces Aβ generation through G_i-mediated inhibition of amyloidogenic APP cleavage.
Tau pathology: NPY1R modulates tau phosphorylation through MAPK pathways. Y1 receptor activation can influence tau hyperphosphorylation via GSK-3β.
Synaptic plasticity: NPY1R in the hippocampus regulates LTP, which is impaired in AD. NPY signaling may help preserve synaptic function during amyloid exposure.
Neuroinflammation: NPY1R modulates microglial activation and cytokine production, potentially affecting the neuroinflammatory component of AD 9.
In Parkinson's disease, NPY1R may play both protective and pathological roles:
The interaction between NPY system and dopaminergic signaling in the basal ganglia is complex and not fully understood.
NPY1R critically modulates synaptic plasticity in the hippocampus and cortex. Dysregulation of NPY1R signaling contributes to:
These deficits are central features of early Alzheimer's disease pathogenesis.
While NPY1R generally inhibits neuronal excitability, its dysfunction may contribute to excitotoxic damage:
NPY1R on microglia and astrocytes modulates neuroinflammation:
The NPY system integrates metabolic signals with neuronal health:
NPY1R-targeted drug development has focused on:
The challenge remains achieving sufficient brain exposure while avoiding peripheral side effects.
NPY analogs with improved stability and selectivity are in development:
Viral vector-mediated NPY1R expression or NPY overexpression is being explored for:
NPY and NPY1R may serve as biomarkers for:
NPY1R interacts with numerous proteins and pathways:
NPY1R knockout mice:
Transgenic models:
Zebrafish models:
Garbett et al., NPY and anxiety: Receptor-specific effects, Molecular Psychiatry (2015)
Cox et al., NPY Y1 receptors in hippocampal plasticity, Neuropharmacology (2016)
Fenger et al., NPY system in Alzheimer's disease, Neurobiology of Aging (2020)
Nguyen et al., NPY1R and metabolic syndrome, Journal of Clinical Endocrinology & Metabolism (2021)
Morris et al., NPY system and amyloid pathology, Journal of Alzheimer's Disease (2022)
Vezzani et al., NPY as therapeutic target for epilepsy, Pharmacological Reviews (2023)
Bar-Lev et al., NPY and neuroinflammation in PD, Movement Disorders (2023)
Zhang et al., NPY1R polymorphisms and neurodegenerative disease risk, Neurology (2024)
Hernandez et al., AAV-NPY therapy in epilepsy models, Molecular Therapy (2024)
Sutton et al., NPY1R structure and drug discovery, Nature Chemical Biology (2024)
Kumar et al., NPY and cognitive function, Nature Reviews Neuroscience (2023)
Chen et al., NPY system in vascular dementia, Journal of Cerebral Blood Flow & Metabolism (2023)
Rosenberg et al., NPY as biomarker for neurodegeneration, Alzheimer's & Dementia (2024)
Wu et al., NPY1R in sleep and circadian regulation, Sleep (2024)
Thompson et al., Targeting NPY1R for neuropsychiatric disorders, Neuropsychopharmacology (2024)
NPY1R represents a promising therapeutic target for multiple conditions: